Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint

被引:101
作者
Duffull, Stephen B. [1 ]
Wright, Daniel F. B. [1 ]
Winter, Helen R. [1 ,2 ]
机构
[1] Univ Otago, Sch Pharm, Dunedin 9054, New Zealand
[2] Global Alliance TB Drug Dev, New York, NY 10005 USA
关键词
pharmacodynamics; pharmacokinetics; pharmacometrics; population analyses; statistical models; CYSTIC-FIBROSIS PATIENTS; DRUG DEVELOPMENT; DOSING STRATEGY; RENAL-FUNCTION; MODEL; ENOXAPARIN; PARAMETERS; DESIGN; ITRACONAZOLE; SIMULATION;
D O I
10.1111/j.1365-2125.2010.03891.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The population analysis approach is an important tool for clinical pharmacology in aiding the dose individualization of medicines. However, due to their statistical complexity the clinical utility of population analyses is often overlooked. One of the key reasons to conduct a population analysis is to investigate the potential benefits of individualization of drug dosing based on patient characteristics (termed covariate identification). The purpose of this review is to provide a tool to interpret and extract information from publications that describe population analysis. The target audience is those readers who are aware of population analyses but have not conducted the technical aspects of an analysis themselves. Initially we introduce the general framework of population analysis and work through a simple example with visual plots. We then follow-up with specific details on how to interpret population analyses for the purpose of identifying covariates and how to interpret their likely importance for dose individualization.
引用
收藏
页码:807 / 814
页数:8
相关论文
共 50 条
[41]   Population pharmacokinetic-pharmacodynamic modeling of ketamine-induced pain relief of chronic pain [J].
Dahan, Albert ;
Olofsen, Erik ;
Sigtermans, Marnix ;
Noppers, Ingeborg ;
Niesters, Marieke ;
Aarts, Leon ;
Bauer, Martin ;
Sarton, Elise .
EUROPEAN JOURNAL OF PAIN, 2011, 15 (03) :258-267
[42]   Pharmacokinetic-Pharmacodynamic Correlation Analysis of Rhodiola crenulata in Rats with Myocardial Ischemia [J].
Jia, Zhixin ;
Zou, Guoming ;
Xie, Yongyan ;
Zhang, Enning ;
Yimingjiang, Mureziya ;
Cheng, Xianlong ;
Fang, Cong ;
Wei, Feng .
PHARMACEUTICALS, 2024, 17 (05)
[43]   Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects [J].
Czock, David ;
Keller, Frieder .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2007, 34 (06) :727-751
[44]   Pharmacokinetic-pharmacodynamic modelling for captopril in healthy anaesthetized piglets [J].
Pereira, CM ;
Tam, YK ;
Coe, JY ;
Olley, PM ;
CollinsNakai, RL .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1996, 17 (05) :365-372
[45]   Pharmacokinetic-pharmacodynamic modeling of doxacurium: Effect of input rate [J].
Zhu, YL ;
Audibert, G ;
Donati, F ;
Varin, F .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1997, 25 (01) :23-37
[46]   Gliclazide:: Pharmacokinetic-pharmacodynamic relationships in rats [J].
Stetinova, V. ;
Kvetina, J. ;
Pastera, J. ;
Polaskova, A. ;
Prazakova, M. .
BIOPHARMACEUTICS & DRUG DISPOSITION, 2007, 28 (05) :241-248
[47]   PHARMACOKINETIC-PHARMACODYNAMIC AND METABOLITE MODELING WITH TOPFIT [J].
TANSWELL, P ;
HEINZEL, G ;
WEISENBERGER, H ;
ROTH, W .
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1995, 33 (10) :550-554
[48]   Pharmacokinetic-pharmacodynamic modeling of daurisoline and dauricine in beagle dogs [J].
Shi, SJ ;
Chen, H ;
Gu, SF ;
Zeng, FD .
ACTA PHARMACOLOGICA SINICA, 2003, 24 (10) :1011-1015
[49]   Amikacin Pharmacokinetic-Pharmacodynamic Analysis in Pediatric Cancer Patients [J].
Alhadab, Ali A. ;
Ahmed, Mariam A. ;
Brundage, Richard C. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (04)
[50]   Personalized pharmacotherapy in oncology: Application of pharmacokinetic-pharmacodynamic criteria [J].
Porta-Oltra, Begona ;
Merino-Sanjuan, Matilde .
FARMACIA HOSPITALARIA, 2021, 45 :45-55